T-cell receptor–peptide–major histocompatibility complex (TCR–pMHC) complex (TCR–pMHC complex)

The **T-cell receptor–peptide–major histocompatibility complex (TCR–pMHC) complex** is the molecular assembly formed when a T-cell receptor (TCR) on the surface of a T lymphocyte specifically binds a peptide fragment presented by a major histocompatibility complex (MHC) protein, typically on the surface of an antigen-presenting cell[1][2][3][5][7]. The TCR is a highly diverse, immunoglobulin superfamily receptor composed primarily of alpha and beta chains (or less frequently, gamma and delta chains), and it recognizes a specific antigenic peptide embedded within the binding groove of an MHC molecule—Class I MHC for CD8+ T cells, or Class II MHC for CD4+ T cells[2][3][5]. This interaction is central to adaptive immunity, initiating intracellular signaling cascades that activate T cells and drive immune responses[6][7]. The specificity and strength of TCR–pMHC binding underlie both protective immunity to pathogens and cancer, as well as pathological conditions such as autoimmunity and transplant rejection. The TCR–pMHC interaction is therefore a major therapeutic target, directly and indirectly modulated by various immune therapies[2][7].

Other names

TCR–MHC-peptide complexT-cell receptor:peptide:MHC complexT-cell receptor–MHC complexT-cell receptor–peptide–MHC complexTCR–pMHCTCR–HLA-peptide complex (in humans)TCR–antigen–MHC complex

Drugs may block downstream signaling from TCR activation (e.g., calcineurin inhibitors prevent NFAT activation after TCR engagement)\nSome antibodies or biologics (e.g., checkpoint inhibitors) modulate the strength or quality of TCR signaling by blocking inhibitory or co-stimulatory receptors\nEngineered TCRs or TCR-mimic therapies target specific tumor or viral peptide–MHC complexes